Furthermore, elevated levels of soluble AXL and MERTK receptors were accompanied by low levels of GAS6 in MS lesions, resulting in the dysregulation of GAS6/TAM signaling and possibly prolonged lesion activity [89]. This evidence concerns the gene GAS6 and myeloid sarcoma.